Retifanlimab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 731, doi. 10.1007/s40265-023-01884-7
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2023 AND VI 83 AND IP 8
Results: 8
1
2
Cipaglucosidase Alfa: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 739, doi. 10.1007/s40265-023-01886-5
- By:
- Publication type:
- Article
3
Androgenetic Alopecia: Therapy Update.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 701, doi. 10.1007/s40265-023-01880-x
- By:
- Publication type:
- Article
4
Ravulizumab: A Review in Generalised Myasthenia Gravis.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 717, doi. 10.1007/s40265-023-01877-6
- By:
- Publication type:
- Article
5
The Role of Vitamin D in Health and Disease: A Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 665, doi. 10.1007/s40265-023-01875-8
- By:
- Publication type:
- Article
6
Omaveloxolone: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 725, doi. 10.1007/s40265-023-01874-9
- By:
- Publication type:
- Article
7
Antibiotics and Probiotics for Irritable Bowel Syndrome.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 687, doi. 10.1007/s40265-023-01871-y
- By:
- Publication type:
- Article
8
Innovation in Targeted Intra-articular Therapies for Osteoarthritis.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 649, doi. 10.1007/s40265-023-01863-y
- By:
- Publication type:
- Article